Sophiris Bio Inc. (NASDAQ:SPHS)’s share price rose 7.5% on Friday . The stock traded as high as $3.30 and last traded at $3.16, with a volume of 2,846,905 shares changing hands. The stock had previously closed at $2.94.

SPHS has been the subject of several analyst reports. Piper Jaffray Cos. assumed coverage on shares of Sophiris Bio in a research note on Tuesday. They issued an “overweight” rating and a $7.00 target price for the company. Maxim Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of Sophiris Bio in a research report on Friday, June 10th. Finally, Echelon Wealth Partners reaffirmed a “buy” rating and set a $5.00 price objective on shares of Sophiris Bio in a research report on Friday, June 10th.

The company’s market capitalization is $64.74 million. The company has a 50-day moving average price of $4.49 and a 200-day moving average price of $2.32.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.